Verrica Pharmaceuticals has reported positive results from the post-hoc pooled analysis of the Phase III CAMP clinical trials of VP-102 in patients with molluscum contagiosum.
Molluscum is a contagious viral skin infection, while VP-102 is a topical solution of 0.7% cantharidin being developed to treat the highly infectious disease.
The CAMP studies assessed the safety and efficacy of the drug candidate. The pooled analysis found statistically significantly higher clearance of all lesions in the VP-102 group.
During the analysis, efficacy was determined as the proportion of participants with complete clearance of lesions in each body location by visit.
The statistically significantly higher clearance with VP-102 was observed across all body regions, including head/neck, chest/abdomen, back/buttocks, as well as upper and lower extremities.
In addition, adverse event rates in patients treated with VP-102 were similar for all locations.
The incidence of treatment-emergent adverse events (TEAEs) was measured depending on application site reactions reported during or following treatment visit one and prior to visit two.
The most common TEAEs were application site vesicles, pruritus, pain, erythema, scab, discolouration, dryness and oedema.
VP-102 Phase III molluscum programme principal investigator Lawrence Eichenfield said: “The results of this study are important, as they suggest that this investigational molluscum treatment can potentially bring about complete clearance, regardless of where on the body the lesion is located.
“If approved, VP-102 may potentially be an important option for physicians, as they can have the option to treat even the most sensitive areas, including the groin, head, and neck.”
The company is presenting the post-hoc pooled analysis data at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast, Hawaii from 18-22 January.